脂肪组织源性干细胞用于治疗气道过敏性疾病的细胞疗法。
Adipose tissue-derived stem cells for cell therapy of airway allergic diseases in mouse.
机构信息
Department of Otorhinolaryngology and Medical Research Institute, Pusan National University School of Medicine, Busan, South Korea.
出版信息
Acta Histochem. 2011 Sep;113(5):501-7. doi: 10.1016/j.acthis.2010.05.003. Epub 2010 Jul 2.
The purpose of this study was to compare murine mesenchymal stem cells (MSCs) isolated from bone marrow (BM) and adipose tissue (AT) for the selection of suitable MSCs in cell therapy of an airway allergic animal model. We compared MSCs of BALB/c mice derived from BM and AT with respect to proliferation potential, immunophenotype, and multilineage differentiation capacity. In proliferation potential, MSCs from AT (ASCs) showed higher fibroblastoid colony-forming units frequencies and colony-forming efficiency than MSCs from BM (BMSCs). The flow cytometry analysis showed that both ASCs and BMSCs expressed MSCs-related antigens (CD90 and CD105), whereas they did not express hematopoiesis-related antigens (CD45 and CD11b). There was no significant difference in adipogenic, osteogenic, and chondrogenic differentiation between the murine ASCs and BMSCs. In conclusion, the present study has shown that ASCs had higher CFU-F frequencies and colony-forming efficiency than BMSCs. ASCs and BMSCs presented a similar surface immunophenotype and multilineage differentiation capacity. Therefore, ASCs in BALB/c mice might be a more useful material for cell therapy of the airway allergic experiment due to the abundance, relatively easy harvesting and high proliferation potential.
本研究旨在比较来源于骨髓(BM)和脂肪组织(AT)的鼠间充质干细胞(MSCs),以选择气道过敏性动物模型细胞治疗中合适的 MSCs。我们比较了 BALB/c 小鼠来源于 BM 和 AT 的 MSCs 在增殖潜能、免疫表型和多向分化能力方面的差异。在增殖潜能方面,来源于 AT(ASCs)的 MSCs 比来源于 BM(BMSCs)的 MSCs 具有更高的成纤维细胞集落形成单位频率和集落形成效率。流式细胞术分析表明,ASCs 和 BMSCs 均表达 MSC 相关抗原(CD90 和 CD105),而不表达造血相关抗原(CD45 和 CD11b)。鼠 ASCs 和 BMSCs 的成脂、成骨和成软骨分化之间无显著差异。综上所述,本研究表明 ASCs 的 CFU-F 频率和集落形成效率高于 BMSCs。ASCs 和 BMSCs 具有相似的表面免疫表型和多向分化能力。因此,由于丰富、相对容易收获和高增殖潜能,BALB/c 小鼠来源的 ASCs 可能是气道过敏性实验细胞治疗的更有用材料。